These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20521434)

  • 1. AAA- a further step towards a moratorium for aspirin in the primary prevention.
    Minar E
    Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin for Primary Prevention of Cardiovascular Disease.
    Kheiri B; Barbarawi M; Bachuwa G; Shapiro MD
    Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005846. PubMed ID: 31163982
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
    Soejima H; Morimoto T; Saito Y; Ogawa H
    Thromb Haemost; 2010 Dec; 104(6):1085-8. PubMed ID: 20941462
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
    Godley RW; Hernandez-Vila E
    Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspirin in primary prevention: USPSTF recommendations.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
    [No Abstract]   [Full Text] [Related]  

  • 6. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
    Tousoulis D
    Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    Matthys F; De Backer T; De Backer G; Stichele RV
    Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing the science of aspirin in primary prevention of vascular events.
    Cardiovasc J Afr; 2007; 18(5):347-8. PubMed ID: 17985039
    [No Abstract]   [Full Text] [Related]  

  • 10. On the potential contribution of aspirin to healthy ageing programmes.
    Morgan GP
    Age Ageing; 2016 Mar; 45(2):e1-3. PubMed ID: 22101149
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
    Upadhaya S; Madala S; Baniya R; Saginala K; Khan J
    Eur J Prev Cardiol; 2019 May; 26(7):746-749. PubMed ID: 30861689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
    Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for the primary prevention of vascular events?
    Morgan G
    Public Health; 2009 Dec; 123(12):787-8. PubMed ID: 19914670
    [No Abstract]   [Full Text] [Related]  

  • 14. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
    Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
    G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aspirin for primary prevention of asymptomatic atherosclerosis].
    Lévesque H
    J Mal Vasc; 2002 Dec; 27(5):263-6. PubMed ID: 12525771
    [No Abstract]   [Full Text] [Related]  

  • 16. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower aspirin doses in dual antiplatelet therapy optimise efficacy and safety: CHARISMA follow-up study.
    Cardiovasc J Afr; 2009; 20(3):205. PubMed ID: 19575092
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
    Barmanray R; Hamblin PS
    Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
    [No Abstract]   [Full Text] [Related]  

  • 19. Aspirin as preventive therapy in patients with asymptomatic vascular disease.
    Berger JS
    JAMA; 2010 Mar; 303(9):880-2. PubMed ID: 20197537
    [No Abstract]   [Full Text] [Related]  

  • 20. [Primary cardiovascular prevention with aspirin].
    Seguí Díaz M; Escobar C; Divisón JA
    Semergen; 2015; 41(5):279-81. PubMed ID: 25622997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.